Business Context and Reporting Period
This Form 8-K filing by CytomX Therapeutics, Inc. (CTMX) reports a corporate governance event dated June 12, 2024. The company is a biopharmaceutical entity incorporated in Delaware and trades on the Nasdaq Global Select Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive appointments and related compensation arrangements rather than financial performance.
Material Changes
The primary material change reported is the appointment of Chris Ogden as Chief Financial Officer (CFO), effective June 15, 2024. Mr. Ogden is being promoted from his previous role as Senior Vice President, Finance and Accounting. He will continue to serve as the Principal Accounting Officer and Principal Financial Officer.
Guidance, Outlook, and Compensation
In connection with the CFO appointment, the Company granted Mr. Ogden the following equity awards under the 2015 Equity Incentive Plan:
- A stock option award to purchase 75,000 shares of common stock at the closing price on the grant date.
- A restricted stock unit (RSU) award for 17,500 shares of common stock.
The filing confirms no family relationships between Mr. Ogden and other directors or officers, and no undisclosed transactions involving Mr. Ogden or his immediate family since the beginning of the last fiscal year. No specific business guidance or risk factors were disclosed in this specific filing.
Investor Verification Checklist
- Verify the effective date of the CFO transition (June 15, 2024).
- Confirm the total equity grant size (75,000 options and 17,500 RSUs) and its impact on dilution.
- Review the Company's proxy statement filed on April 4, 2024, for Mr. Ogden's full biographical data.
- Check subsequent filings for the departure of the previous CFO, if applicable.